BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Billes SK, Cowley MA. Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 2008;33:1287-97. [PMID: 17687262 DOI: 10.1038/sj.npp.1301526] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Zoli M, Picciotto MR. Nicotinic regulation of energy homeostasis. Nicotine Tob Res 2012;14:1270-90. [PMID: 22990212 DOI: 10.1093/ntr/nts159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
2 Doan KV, Kinyua AW, Yang DJ, Ko CM, Moh SH, Shong KE, Kim H, Park SK, Kim DH, Kim I, Paik JH, DePinho RA, Yoon SG, Kim IY, Seong JK, Choi YH, Kim KW. FoxO1 in dopaminergic neurons regulates energy homeostasis and targets tyrosine hydroxylase. Nat Commun 2016;7:12733. [PMID: 27681312 DOI: 10.1038/ncomms12733] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
3 Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-9. [PMID: 18997675 DOI: 10.1038/oby.2008.461] [Cited by in Crossref: 199] [Cited by in F6Publishing: 183] [Article Influence: 14.2] [Reference Citation Analysis]
4 Clapper JR, Athanacio J, Wittmer C, Griffin PS, D'souza L, Parkes DG, Roth JD. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. European Journal of Pharmacology 2013;698:292-8. [DOI: 10.1016/j.ejphar.2012.11.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
5 Umezu T. Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice. ISRN Pharmacol 2012;2012:170981. [PMID: 22530136 DOI: 10.5402/2012/170981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Hausenloy DJ. Contrave™: novel treatment for obesity. Clinical Lipidology 2009;4:279-85. [DOI: 10.2217/clp.09.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Bello NT, Walters AL, Verpeut JL, Cunha PP. High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor. J Obes 2013;2013:457047. [PMID: 23431425 DOI: 10.1155/2013/457047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
8 He F, Zhang P, Zhang Q, Qi G, Cai H, Li T, Li M, Lu J, Lin J, Ming J, Tian B. Dopaminergic Projection from Ventral Tegmental Area to Substantia Nigra Pars Reticulata Mediates Chronic Social Defeat Stress-Induced Hypolocomotion. Mol Neurobiol 2021. [PMID: 34382160 DOI: 10.1007/s12035-021-02522-7] [Reference Citation Analysis]
9 Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014;84:1-11. [PMID: 24754973 DOI: 10.1016/j.phrs.2014.04.004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
10 Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 2010;97:63-83. [PMID: 20688100 DOI: 10.1016/j.pbb.2010.07.020] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
11 Ueno T, Tomita J, Kume S, Kume K. Dopamine modulates metabolic rate and temperature sensitivity in Drosophila melanogaster. PLoS One 2012;7:e31513. [PMID: 22347491 DOI: 10.1371/journal.pone.0031513] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
12 Lai CH. Duloxetine related binge eating behaviors: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1581-2. [PMID: 19778574 DOI: 10.1016/j.pnpbp.2009.09.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010;636:88-95. [PMID: 20385125 DOI: 10.1016/j.ejphar.2010.03.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
14 Calandra C, Russo RG, Luca M. Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study. Psychiatr Q 2012;83:177-85. [DOI: 10.1007/s11126-011-9192-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
15 Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010;35:1464-76. [PMID: 20200509 DOI: 10.1038/npp.2010.16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
16 Lajtha A, Sershen H. Heterogeneity of Reward Mechanisms. Neurochem Res 2010;35:851-67. [DOI: 10.1007/s11064-009-0096-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
17 Wright FL, Rodgers RJ. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology (Berl) 2013;228:291-307. [PMID: 23455599 DOI: 10.1007/s00213-013-3036-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
18 Janhunen SK, la Fleur SE, Adan RA. Blocking alpha2A adrenoceptors, but not dopamine receptors, augments bupropion-induced hypophagia in rats. Obesity (Silver Spring) 2013;21:E700-8. [PMID: 23894096 DOI: 10.1002/oby.20581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Beeler JA, Frazier CR, Zhuang X. Putting desire on a budget: dopamine and energy expenditure, reconciling reward and resources. Front Integr Neurosci 2012;6:49. [PMID: 22833718 DOI: 10.3389/fnint.2012.00049] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
20 van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European Neuropsychopharmacology 2012;22:290-9. [DOI: 10.1016/j.euroneuro.2011.07.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
21 Clapham JC, Arch JR. Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacol Ther 2011;131:295-308. [PMID: 21514319 DOI: 10.1016/j.pharmthera.2011.04.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
22 Clapham JC. Central control of thermogenesis. Neuropharmacology 2012;63:111-23. [PMID: 22063719 DOI: 10.1016/j.neuropharm.2011.10.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
23 Song Y, Pan X, Liu C, Xiang H. Role of nociceptive arcuate nucleus neurons in chloroquine-induced pruritic behaviors in mice. J Huazhong Univ Sci Technol [Med Sci ] 2012;32:919-22. [DOI: 10.1007/s11596-012-1058-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Hollstein T, Basolo A, Ando T, Votruba SB, Krakoff J, Piaggi P. Urinary Norepinephrine Is a Metabolic Determinant of 24-Hour Energy Expenditure and Sleeping Metabolic Rate in Adult Humans. J Clin Endocrinol Metab 2020;105:dgaa047. [PMID: 32002540 DOI: 10.1210/clinem/dgaa047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Roitman MF, Wescott S, Cone JJ, McLane MP, Wolfe HR. MSI-1436 reduces acute food intake without affecting dopamine transporter activity. Pharmacol Biochem Behav 2010;97:138-43. [PMID: 20478327 DOI: 10.1016/j.pbb.2010.05.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
26 Simonds SE, Pryor JT, Cowley MA. Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. Physiology & Behavior 2018;194:184-90. [DOI: 10.1016/j.physbeh.2018.05.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rajput SK, Krishnamoorthy S, Pawar C, Kaur N, Monga V, Meena CL, Jain R, Sharma SS. Antiepileptic potential and behavioral profile of l-pGlu-(2-propyl)–l-His–l-ProNH2, a newer thyrotropin-releasing hormone analog. Epilepsy & Behavior 2009;14:48-53. [DOI: 10.1016/j.yebeh.2008.10.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
28 Arch JR, Trayhurn P. Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification. Front Physiol 2013;4:64. [PMID: 23580228 DOI: 10.3389/fphys.2013.00064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
29 Enriori PJ, Sinnayah P, Simonds SE, Garcia Rudaz C, Cowley MA. Leptin action in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of systemic leptin resistance. J Neurosci. 2011;31:12189-12197. [PMID: 21865462 DOI: 10.1523/JNEUROSCI.2336-11.2011] [Cited by in Crossref: 189] [Cited by in F6Publishing: 129] [Article Influence: 17.2] [Reference Citation Analysis]
30 McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E. Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord 2013;15:PCC. [PMID: 24171147 DOI: 10.4088/PCC.12m01494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
31 Carrasco MC, Vidal J, Redolat R. Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. Behav Processes 2013;98:117-24. [PMID: 23727544 DOI: 10.1016/j.beproc.2013.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Ahmed M, El-Bakly WM, Zaki AM, abd Alzez LF, El serafi O. Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha. J Pharm Pharmacol 2014;66:793-801. [PMID: 24471744 DOI: 10.1111/jphp.12213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Roux J, Dura E, Villard L. Tyrosine hydroxylase deficit in the chemoafferent and the sympathoadrenergic pathways of the Mecp2 deficient mouse. Neuroscience Letters 2008;447:82-6. [DOI: 10.1016/j.neulet.2008.09.045] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
34 Mercader J, Sabater AG, Le Gonidec S, Decaunes P, Chaplin A, Gómez-Zorita S, Milagro FI, Carpéné C. Oral Phenelzine Treatment Mitigates Metabolic Disturbances in Mice Fed a High-Fat Diet. J Pharmacol Exp Ther 2019;371:555-66. [PMID: 31270215 DOI: 10.1124/jpet.119.259895] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Hobgood DK. Personality and illness: genetic connections? Med Hypotheses 2011;76:89-93. [PMID: 20826063 DOI: 10.1016/j.mehy.2010.08.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
36 Stefanidis A, Man Lee CC, Brown WA, Oldfield BJ. Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model. Surg Obes Relat Dis 2017;13:291-304. [PMID: 27988274 DOI: 10.1016/j.soard.2016.09.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Navarro M, Luhn KL, Kampov-Polevoy AB, Garbutt JC, Thiele TE. Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice. Alcohol Clin Exp Res 2019;43:783-90. [PMID: 30817015 DOI: 10.1111/acer.13992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]